Correlation of germline MET mutation with response to the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Results from a multicenter phase II study (MET111644).
Year: 2012
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Brigham and Women's Hospital, National Institutes of Health, Harvard University, University of California, San Francisco, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute, National Cancer Institute, Center for Cancer Research, Dana-Farber Brigham Cancer Center, Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2581807615